Sugi Predict

Sugi Predict / Compounds / SCHEMBL15069582

SCHEMBL15069582

SCHEMBL15069582

COc1ncc(Br)c2ccn(S(=O)(=O)c3ccc(C)cc3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ ABL1 P00519 2/20 0.38
▸ BCR P11274 2/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ ALDH3A1 P30838 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.38
▸ HTR6 P50406 5/20 0.37
▸ RAPGEF4 Q8WZA2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TUBB4A P04350 1/20 0.36
▸ TUBB P07437 1/20 0.36
▸ TUBA3C P0DPH7 1/20 0.36
▸ TUBA1B P68363 1/20 0.36
▸ TUBA4A P68366 1/20 0.36
▸ TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16923796 0.89 HTR6 (0.48) L3MBTL1POLBHTTHTR6MEN1
SCHEMBL31589841 0.85 L3MBTL1 (0.44) L3MBTL1CA1CA2BRD4POLB
SCHEMBL30999225 0.85 L3MBTL1 (0.41) L3MBTL1CA1CA2BRD4POLB
SCHEMBL19662371 0.85 L3MBTL1 (0.45) L3MBTL1CA1CA2ABL1BCR
SCHEMBL31590165 0.83 L3MBTL1 (0.40) L3MBTL1CA1CA2BRD4POLB
SCHEMBL16739069 0.82 L3MBTL1 (0.43) L3MBTL1CA1CA2ABL1BCR
SCHEMBL2128761 0.82 ABL1 (0.45) L3MBTL1CA1CA2ABL1BCR
SCHEMBL30999221 0.82 L3MBTL1 (0.39) L3MBTL1CA1CA2BRD4POLB
SCHEMBL16923795 0.82 PIK3C3 (0.37) HTTHTR6
SCHEMBL27041372 0.81 L3MBTL1 (0.39) L3MBTL1BRD4POLBALDH3A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 — — US disclosed
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
EP-4342543-B1 TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER HOFFMANN LA ROCHE (CH) 2026-04-29 — — EP disclosed
US-20260092065-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR INCYTE CORP (US) 2026-04-02 — — US disclosed
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 — — US disclosed
EP-4653436-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) 2025-11-26 — — EP disclosed
US-12459943-B2 Crystalline solid forms of a BET inhibitor INCYTE CORPORATION (US) 2025-11-04 — — US disclosed
EP-4637754-A2 SELECTIVE BET INHIBITORS AND USES THEREOF Tay Therapeutics Limited (GB) 2025-10-29 — — EP disclosed
US-12384777-B2 Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts Tay Therapeutics Limited (GB) 2025-08-12 — — US disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 — — EP disclosed
US-9321765-B2 Crystalline bromodomain inhibitors ABBVIE INC. (US) 2016-04-26 — — US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 — — US disclosed
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. 2016-02-11 — — US disclosed
US-20150005340-A1 CRYSTALLINE BROMODOMAIN INHIBITORS ABBVIE INC. 2015-01-01 — — US disclosed
WO-2014206345-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
WO-2014206150-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
WO-2014210425-A1 CRYSTALLINE BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 — — WO disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 — — EP disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459943-B2 Crystalline solid forms of a BET inhibitor BRD1, BRD3, BRD2 L3MBTL1 708/4885CA1 3670/4885CA2 4071/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 L3MBTL1 1184/4885CA1 1571/4885CA2 2735/4885
US-20160039821-A1 TETRACYCLIC BROMODOMAIN INHIBITORS BRD3, BRD4, BRD1 L3MBTL1 1417/4885CA1 1950/4885CA2 2329/4885
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC L3MBTL1 933/4885CA1 4468/4885CA2 3396/4885
US-20260092065-A1 CRYSTALLINE SOLID FORMS OF A BET INHIBITOR BRD2, BRDT, BRD1 L3MBTL1 632/4885CA1 4052/4885CA2 4427/4885
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD BRDT, BET1, PHKB L3MBTL1 920/4885CA1 4625/4885CA2 2538/4885
US-12384777-B2 Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts TPMT, IL5, P2RY6 L3MBTL1 4198/4885CA1 4869/4885CA2 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback